CDK8-IN-20 

CDK8-IN-20 (Compound 67j) is a selective, potent and orally active type I CDK8 inhibitor with an IC₅₀ of 70.5 nM. CDK8-IN-20 shows IC₅₀ values of 147.8, 726.9 and 217.4 nM for homologous kinase CDK19, CDK7 and CDK9. CDK8-IN-20 can inhibit the Wnt/β-catenin pathway and downregulate the expression of β-catenin, Cyclin D1, and c-Myc. CDK8-IN-20 can induce ROS production and cause G2/M and S phase arrest. CDK8-IN-20can be used for the research of cancer, such as colon cancer^[1].

CDK8-IN-20 can inhibit HCT-116, HT-29 and SW-480 cell proliferation with an IC₅₀ values of 5.9, 17.93 and 9.52 μM and has low cytotoxicity for normal gastric mucosal epithelial cells GES-1 (IC₅₀ > 100 μM)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

469.51

C₂₂H₂₃N₅O₅S

O=C(C1=CC=CN1)NC2=CC(NS(=O)(C3=C(C)C=C(C(N4C)=C3)N(C)C4=O)=O)=CC(OC)=C2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Du J, et al. Design and synthesis of a 1,3,6-trimethyl-1H-benzo[d]imidazole-5-sulfonamide derivative as a type I CDK8 inhibitor against colorectal cancer. Bioorg Chem. 2025 Nov 26;168:109297.  [Content Brief]